Pricing6 min read
How to Buy Peptides in Bulk & Save
Buying more vials for your own multi-month protocol can cut your $/mg. How volume tiers, coupon stacking, and stability windows actually work.
Peptide News & Analysis
FDA actions, trial readouts, vendor coverage and pricing reports — curated for peptide buyers and clinicians.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Latest News
Regulatory4 min read
FDA Hits 25 More Telehealth GLP-1 Sellers
FDA posted 25 new warning letters June 16 to telehealth firms over compounded semaglutide and tirzepatide claims. What it signals and what's still legal.
Industry4 min read
BELIEVE Trial: GLP-1 Combo Keeps 92% Fat Loss
Bimagrumab plus semaglutide hit 22.1% weight loss with 92.8% from fat in the BELIEVE trial. What it means for muscle-preserving peptide stacks.
Industry4 min read
GLP-1 Users Walk 560 Fewer Steps a Day: ENDO 2026
A Fitbit study at ENDO 2026 found GLP-1 users moved less after starting treatment. What it means for muscle, results, and how to push back.
Industry5 min read
Enicepatide: Roche's CT-388 Hits 22.5% at ADA 2026
Roche's enicepatide (CT-388) hit 22.5% placebo-adjusted weight loss at ADA 2026. What the dual GLP-1/GIP data means for buyers right now.
Trials6 min read
Retatrutide Cuts Knee OA Pain 73%, Sleep Apnea 61%
TRIUMPH-1's ADA 2026 baskets show retatrutide cut WOMAC knee pain 73% and sleep apnea events 61% — beyond weight loss. What it means for buyers.
Industry4 min read
GLP-1s Cut 30 lbs in Menopause: ADA Data
New ATTAIN post-hoc data: women lost up to 30.4 lbs at every menopause stage on an oral GLP-1. What it means and where buyers source GLP-1 peptides.
Trials5 min read
Retatrutide TRANSCEND-T2D-1: 16% Loss in Diabetes
Retatrutide's first Phase 3 diabetes trial hit 1.9% A1C drops and 15.3% weight loss at 40 weeks — published in The Lancet. What it means for buyers.
Industry6 min read
Petrelintide: 10.7% Weight Loss, Placebo-Like GI
Roche's amylin drug petrelintide hit 10.7% weight loss at ADA 2026 with placebo-like GI tolerability. What the ZUPREME-1 data means for buyers.
Industry4 min read
Zenagamtide (Amycretin): 14.6% Loss at ADA 2026
Novo's single-molecule GLP-1/amylin agonist hit 14.6% weight loss and 1.71% A1C drop in Phase 2. What zenagamtide (amycretin) means for buyers.
Industry4 min read
Elecoglipron: AstraZeneca's Oral GLP-1 at ADA 2026
AstraZeneca's oral GLP-1 elecoglipron hit Phase 2b endpoints in VISTA and SOLSTICE. Full weight-loss data drops at ADA June 8. What it means for buyers.
Industry6 min read
CagriSema Diabetes Data Debuts at ADA 2026
Novo's amylin/GLP-1 combo unveils first REIMAGINE diabetes results June 7 — 14.2% weight loss, 1.91% A1C drop. What it means for buyers.
Industry6 min read
Pep19: Peptide Cuts Visceral Fat 17%, No GLP-1
Pep19 cut visceral fat 17% and improved sleep in a 60-day trial — without GLP-1. A CB1 inverse-agonist peptide now sold as Nutroslim. What the data shows.
Industry7 min read
Do GH Peptides Desensitize the Pituitary?
Community protocols cycle 8 weeks on, 8 off to avoid desensitization. The trial data tells a more nuanced story — by peptide and by receptor.
Industry5 min read
Why GLP-1 Weight Loss Stalls: NIH Finds the Mechanism
NIH Nature Metabolism study: semaglutide plateaus happen because hindbrain neurons shut down cAMP signaling. PDE4 inhibitors may break it.
Industry4 min read
VC-Funded Peptide Startups Race to Build Before FDA Rules
Venture-backed startups raised $22M+ betting on peptide legalization this summer. Who they are, what they sell, and what it means for buyers.
Industry5 min read
GLP-1s Cut Cancer Metastasis Risk Up to 50%: ASCO Data
ASCO 2026 data: semaglutide and liraglutide users had 36-50% lower metastasis rates across lung, breast, colorectal, and liver cancers. The buyer breakdown.
Industry8 min read
What Is Bacteriostatic Water? Uses, Safety & Storage
One ingredient separates bacteriostatic water from sterile water — and that ingredient is the entire reason multi-dose peptide vials work.